Evidence map›Paper›PMID 35380278›Full record

SynthesisArchives of gynecology and obstetrics2022

The cost-effectiveness of bivalent, quadrivalent, and nine-valent HPV vaccination in Asia: a systematic review.

Ke Zhu, Yuke Tian, Xiaomei Dong, Babatunde O Akinwunmi, Casper J P Zhang, Jian Huang, Wai-Kit Ming

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Archives of gynecology and obstetrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 4 countries.

Ke ZhuDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, China.
Yuke TianDepartment of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xiaomei DongDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, China.
Babatunde O AkinwunmiDepartment of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Casper J P ZhangSchool of Public Health, LSK Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Jian HuangSingapore Institute for Clinical Sciences (SICS), the Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Wai-Kit MingDepartment of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, China. wkming@connect.hku.hk.
Jinan University · CNCity University of Hong Kong · HKHarvard University · USSingapore Institute for Clinical Sciences · SGUniversity of Electronic Science and Technology of China · CNUniversity of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to systematically review the cost-effectiveness of HPV vaccination in Asia.

methodsWe performed a systematic review of papers indexed in PubMed, Scopus, and Web of Science covering the period from 1 January 2000 to 13 August 2020.

resultsSixteen studies were included in the review. Half of them (8 studies) evaluated the cost-effectiveness of HPV vaccination in high-income countries and regions (HICs) while the other eight studies were set in low- and middle-income countries and regions (LMICs). In HICs, the implementation of bivalent, quadrivalent and nine-valent HPV vaccination was all shown to be cost-effective. Most studies (7/8) also showed that it was cost-effective to implement bivalent, quadrivalent, and nine-valent HPV vaccines in LMICs. However, one study concluded that it was not cost-effective to implement bivalent HPV vaccination in Thailand.

conclusionIn general, the implementation of bivalent, quadrivalent and nine-valent HPV vaccination for adolescent girls was cost-effective in both high-income countries and regions and low- and middle-income countries and regions in Asia. Policy makers in HICs could consider expanding the target vaccinated population, while for LMICs it is essential to reduce HPV vaccine price to a level at which the implementation of HPV vaccination is cost-effective.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsAdolescentCost-Benefit AnalysisFemaleHumansThailandVaccinationPapillomavirus VaccinesAsiaCost-effectivenessHPV vaccinationSystematic review

Identifiers

PMID35380278
OpenAlexW4225968187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.